Merrill maintains sell rating for Amylin

Amylin Pharmaceuticals Inc: was kept at its sell rating by Merrill Lynch analyst Thomas McGahren. The company reported fourth-quarter 2005 loss per share of $0.61, consistent with its guidance for a loss of $0.60 to 0.63. Company guidance for 2006 includes total revenue of about $350 million compared with Merrill's prior estimate of $372 million. The analyst maintains its 2006 loss per share estimate at $1.80. Shares of the San Diego pharmaceutical company were down 9 cents, or 2.36%, at $37.20 on volume of 3,988,538 shares versus the three-month running average of 2,032,390 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.